{"adverse_reactions":["ADVERSE REACTIONS"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY"],"contraindications":["CONTRAINDICATIONS"],"description":["DESCRIPTION"],"dosage_and_administration":["DOSAGE & ADMINISTRATION"],"effective_time":"20161003","how_supplied":["HOW SUPPLIED"],"id":"3dfd2c86-648b-640a-e054-00144ff8d46c","indications_and_usage":["INDICATIONS & USAGE"],"openfda":{},"overdosage":["OVERDOSAGE After oral administration of lovastatin to mice the median lethal dose observed was >15 g/m 2. Until further experience is obtained, no specific treatment of overdosage with lovastatin can be recommended. The dialyzability of lovastatin and its metabolites in man is not known at present"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION MM1"],"precautions":["PRECAUTIONS"],"set_id":"fe5c5d22-5299-4324-94ab-792e859acedb","spl_product_data_elements":["Lovastatin Lovastatin LACTOSE MONOHYDRATE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE POLOXAMER 188 SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN TALC BUTYLATED HYDROXYANISOLE LOVASTATIN LOVASTATIN TABLET CTI;143"],"storage_and_handling":["STORAGE AND HANDLING"],"version":"3","warnings":["WARNINGS"]}